Health Canada has conditionally greenlit the medication lecanemab for slowing the progression of early-stage Alzheimer’s disease, sparking questions regarding its efficacy and accessibility in Canada.
Lecanemab, a synthetic antibody administered via intravenous infusion, is designed to target the accumulation of amyloid plaque in the brain, a key characteristic of Alzheimer’s disease. While it does not offer a cure or the ability to restore lost memories, it represents the first disease-modifying Alzheimer’s treatment approved for use in Canada, as per the Alzheimer Society of Canada.
The drug, also known as Leqembi, is specifically approved for individuals with mild cognitive impairment and early-stage Alzheimer’s disease. Patients must demonstrate the presence of amyloid plaque in the brain and undergo testing for gene variants linked to potential adverse effects. Eligibility is restricted to patients with a single or no copy of the APOE4 gene variant to minimize the risk of brain swelling or bleeding.
Concerns now revolve around the drug’s effectiveness and its potential impact on Canada’s healthcare system, prompting considerations from individuals with the disease, their families, healthcare providers, and governmental bodies.
Dr. Sharon Cohen, medical director at Toronto Memory Program, and an investigator in the drug’s clinical trials, highlighted the significance of this approval and emphasized the need for further advancements in the field. Ongoing monitoring through specialized diagnostics like PET scans or MRIs is necessary for individuals receiving lecanemab infusions every two weeks through an IV.
While the approval of lecanemab marks a positive step in Alzheimer’s treatment, questions remain about its cost-effectiveness and real-world impact on patients’ independence. The Alzheimer’s Society advocates for swift public funding and market availability of the drug to ensure equitable access for all eligible patients, considering its approximate yearly cost of $26,000 US in other countries.
As the healthcare landscape navigates this new treatment option, investments in resources, infrastructure, training, and healthcare pathways are essential to deliver these treatments effectively and equitably, as per the Alzheimer’s Society.